Jonathan Hampshire

Jonathan Hampshire

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PPPatrizia Pannucci
Patrizia Pannucci
SJSophie Jefferson
Sophie Jefferson
JHJonathan Hampshire
Jonathan Hampshire
SCSamantha Cooper
Samantha Cooper
SHStephen Hill
Stephen Hill
Jeanette WoolardJeanette Woolard
Jeanette Woolard
The clinical manifestations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection responsible for coronavirus disease 2019 (COVID-19) commonly include dyspnoea and fatigue, and they primarily involve the lungs. However, extra-pulmonary organ dysfunctions, particularly affecting the cardiovascular system, have also been observed following COVID-19 infection. In this context, several cardiac complications have been reported, including hypertension, thromboembolism, arrythmia and heart failure, with myocardial injury and myocarditis being the most frequent. These secondary myocardial inflammatory responses appear to be associated with a poorer disease course and increased mortality in patients with severe COVID-19. In addition, numerous episodes of myocarditis have been reported as a complication of COVID-19 mRNA vaccinations, especially in young adult males. Changes in the cell surface expression of angiotensin-converting enzyme 2 (ACE2) and direct injury to cardiomyocytes resulting from exaggerated immune responses to COVID-19 are just some of the mechanisms that may explain the pathogenesis of COVID-19-induced myocarditis. Here, we review the pathophysiological mechanisms underlying myocarditis associated with COVID-19 infection, with a particular focus on the involvement of ACE2 and Toll-like receptors (TLRs).

9 June 2026 in Heart
Verified
Journal Article
Closed access
PDF file
PTPok-Tin Tang
Pok-Tin Tang
AAAlexandre Almorad
Alexandre Almorad
GVGiampaolo Vetta
Giampaolo Vetta
JCJia H Chan
Jia H Chan
JHJonathan Hampshire
Jonathan Hampshire
MGMatthew R Ginks
Matthew R Ginks
Background Patients undergoing catheter ablation (CA) for persistent atrial fibrillation (PsAF) experience high rates of AF recurrence. Direct current cardioversion (DCCV) is often performed prior to CA, with variable post-DCCV duration of sinus rhythm (SR). Objective We aimed to determine whether shorter SR duration after DCCV is associated with AF recurrence after subsequent CA. Methods We performed an international multicentre retrospective study of patients undergoing first-time CA for PsAF between 2015 and 2024 with a prior DCCV. SR duration after the last DCCV preceding CA was recorded. The primary outcome was freedom from atrial arrhythmia after CA (after a 56-day postablation blanking period). Results 938 patients undergoing first-time CA for PsAF were identified from six centres and categorised by post-DCCV SR duration: 31 days (group 3, n=490). Over median post-CA follow-up of 511 days, 512 patients (55%) experienced atrial arrhythmia recurrence. There was no significant between-group difference in freedom from atrial arrhythmia (log-rank p=0.10). When analysed as a continuous variable in a Cox regression model, there was no association between post-DCCV SR duration and time to first recurrence of atrial arrhythmia (HR per 10-day increment 1.00, 95% CI 1.00 to 1.01, p=0.07). In secondary analyses, there were significantly more blanking period arrhythmias in groups 1 and 2 compared with group 3 (both pairwise p<0.001), and presentation for CA in persistent atrial arrhythmia was associated with a time-dependent increased risk of atrial arrhythmia recurrence compared with presentation in SR. Conclusion In this large multicentre cohort, shorter duration of SR after DCCV was associated with blanking period arrhythmia after subsequent CA, but we did not find evidence of an association with long-term AF recurrence. Clinicians should consider these findings when making decisions regarding suitability for CA or predicting long-term CA success.